NCT06566391View on ClinicalTrials.gov

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Melanoma

Interventions

DRUG

Ipilimumab

Nivolumab and Ipilimumab (sequential) for a total of four doses followed by Nivolumab

Trial Locations (1)

20141

Istituto Europeo di Oncologia, Milan

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

European Institute of Oncology

OTHER